While maximal peptide activity in healthy rats was achieved up to 7-8 months, the data suggest that the peptides act as LH-signaling amplifiers with the potential to improve the magnitude and duration of the effect in human disease states such as hypogonadism. Here, PLOD1 is linked to hypogonadism.